Novelogics Biotechnology Inc.
2900-550 Burrard St.
Member Sector: Biopharmaceuticals
Novelogics is developing antibody immunotherapy drugs for cancer. They have identified an overlooked area in cancer biology that they believe represents a missing piece of the ‘cancer puzzle’. Unlike antibody drugs that attach directly to cells, their proprietary “antibody immunotherapy” acts as an “Interceptor” of unattached immunosuppressive proteins that have the capacity to shut down critical cancer-killing immune cells. The drug is specifically designed to enable effective restoration of these immune cells and to limit further immune suppression, thereby facilitating safe treatment for cancer patients while significantly extending their overall survival times and improving their quality of life.